Pharmacogenetics

Pharmacogenetics investigates how genetic variation influences drug metabolism and individual responses to therapeutic compounds. As an important component of precision medicine, pharmacogenetics helps researchers better understand the relationship between genetic biomarkers and pharmacological pathways.

Genetic differences in enzymes, transport proteins, and metabolic pathways can influence the uptake, activation, or breakdown of therapeutic compounds. The analysis of pharmacogenetic biomarkers therefore plays an important role in biomarker discovery, translational research, and drug development.

Molecular methods such as quantitative polymerase chain reaction (qPCR) enable rapid and reliable detection of genetic variants associated with drug metabolism. These methods support pharmacogenetics research through sensitive and specific biomarker analysis.

Pharmacogenetic Biomarkers in Oncology Research

The investigation of genetic biomarkers involved in drug metabolism is becoming increasingly important in oncology and precision medicine research. One of the most widely studied pharmacogenetic biomarkers is the DPYD gene, which encodes the enzyme dihydropyrimidine dehydrogenase (DPD). Variants within DPYD are frequently investigated in pharmacogenetics, pharmacogenomics, molecular genetics, and translational research. Molecular analysis of these variants supports investigations of genetic variation, population genetics, biomarker development, and metabolic pathways.

BIOTYPE provides the ExaccType DPYD Kit for the analysis of pharmacogenetic DPYD variants, supporting research laboratories in the investigation of genetic variation relevant to precision medicine and oncology research.